PI3K/AKT/mTOR通路
蛋白激酶B
癌症研究
淋巴细胞白血病
医学
PTEN公司
RPTOR公司
作者
Li-Xiao Shi,Jian-Hua Wang,Xiao-Dong Shi
出处
期刊:Zhongguo shi yan xue ye xue za zhi / Zhongguo bing li sheng li xue hui = Journal of experimental hematology / Chinese Association of Pathophysiology
日期:2016-08-01
卷期号:24 (4): 1269-1274
被引量:1
标识
DOI:10.7534/j.issn.1009-2137.2016.04.058
摘要
The PI3K/Akt/mTOR signaling pathway plays a central role in cell growth, proliferation and survival in physiological conditions. This signal pathway is considered to be an innovative targeted therapy of cancer, and its abnormal activation has been proved to be related to T-cell acute lymphoblastic leukemia (T-ALL) .Despite improved treatment strategies, such as multi-drug combination, high-dose chemotherapy and all kinds of application and popularization of hematopoietic stem cell transplantation, children with drug resistance or relapse T-ALL are still rather worse and its overall outcome and prognosis are much poorer than the more common B-lineage ALL. Therefore, more effective and less cytotoxic treatment targeted strategies for leukemia greatly needed. This review focuses on the relationship between the PI3k/Akt/mTOR pathway and the pediatric T-ALL, so as to reveal the exact molecular mechanism of T-ALL and provide more directions for its treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI